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Renal response to ANP in normal dogs during extreme inhibition of
distal Na transport. Atrial natriuretic peptide (ANP) is thought to exert
its major effect within the cortical and inner medullary collecting ducts
(CCD and IMCD) by inhibiting Na transport along conductive chan-
nels and electroneutral pathways. These transport routes are also
thought to be inhibited by a combination of amiloride, thiazide and
bradykinin. We tested the ability of normal dogs to respond to ANP
when various combinations of these Na4 transport inhibitors were
present. In 24 dogs ANP raised UNaV from 31 6 to 223 41 sEq/min
(P < 0.05), a of 192 Eq/min. Bradykinin alone did not depress
UNaV in response to an ANP infusion. In the presence of extreme
natriuresis caused by amiloride and thiazide, the response to ANP was
magnified, presumably due to augmented Na delivery to the CCD and
IMCD. When distal delivery of Na to one kidney was controlled by
aortic clamping in the presence of amiloride, thiazide and bradykinin,
LUNaV in response to ANP was depressed (48 vs. 168 jsEq/min). We
conclude that in the presence of extreme inhibition of Na transport
within the collecting ducts, ANP can still cause a further natriuresis,
probably in the absence of augmented distal Na delivery.
The cardiac-derived hormone atrial natriuretic peptide (ANP)
has several sites of action within the kidney. There is a
vasoactive effect leading to a rise in glomerular filtration rate
(GFR), an effect on the juxtaglomerular (JG) apparatus to
suppress renin secretion, and a tubular effect resulting in
increased urinary sodium excretion [1]
Although receptor sites for ANP have been identified in
various nephron segments [1—4], the major site of action for
inhibition of Na transport appears to be within the collecting
duct system [1, 5]. There is a minor site of action within the
cortical collecting duct (CCD) and a major site of action at the
inner medullary collecting duct (IMCD) [1, 4]. No convincing
effect for ANP inhibiting Na transport in the proximal convo-
luted tubule or ascending limb of the loop of Henle has been
demonstrated [3, 61. Sodium reabsorption in the CCD and
IMCD occurs along conductive channels or by electroneutral
symporters [6]. According to current evidence, the conductive
channels are inhibited by ANP, amiloride and probably kinins
[6], whereas the electroneutral pathways are inhibited by ANP,
bradykinin and thiazides [6]. The conductive Na channel and
Received for publication October 7, 1992
and in revised form January 27, 1993
Accepted for publication January 28, 1993
© 1993 by the International Society of Nephrology
the electroneutral NatCl cotransporter pathways represent
separate mechanisms for Na entry into the cell. The electro-
neutral pathway is thought to function only within the CCD.
In the absence of physiological damping (such as, due to renal
nerves or angiotensin) the major determinant of an ANP-
induced natriuresis should be the combination of Na delivei y
to the inner collecting duct from more proximal sites and the
magnitude of the inhibitory effect on Na transport at that site.
Given the present interest in the possible application of ANP in
refractory edema states [7, 81, a condition where potent diuret-
ics are often used, it was the object of the present study to
determine whether ANP could produce an additive natriuretic
effect in the presence of extreme inhibition of Na transport
within the collecting duct when "delivery" effects to that site
were controlled by means of aortic clamping.
Methods
Studies were performed on acute dogs of either sex, weighing
between 10 and 16 kg and chosen for good health. All dogs were
kept in the Animal Centre for approximately three to four days
prior to use on a diet averaging 45 mEq Na per day. Food was
withdrawn overnight prior to an experiment, but water was
allowed ad libitum. Anaesthetic induction was carried out with
i.v. sodium pentobarbital (25 mg/kg), with small supplemental
doses given as necessary throughout the study. Intubation was
carried out with a cuffed endotracheal tube, and the animals
were then ventilated with a Harvard Dog Respirator. Temper-
ature was measured by a rectal thermometer and maintained as
necessary with heating pads. Mean arterial blood pressure
(ABP) was measured by mercury manometry through a PE 240
catheter placed in the abdominal aorta through the femoral
artery. In some studies, a similar catheter was also placed in a
carotid artery for identical purposes. A PE 240 catheter was
also placed in the contralateral femoral artery for blood sam-
pling. A PE 50 catheter was placed by percutaneous puncture in
an antecubital vein for the administration of inulin and sodium
para-aminohippurate (PAH) by constant infusion pump at 0.5
mI/mm. The former marker was used to measure GFR and the
latter to measure renal plasma flow (CPAH). The constant
infusion technique was used to measure all clearances [9, 101.
Blood was sampled at the midpoint of a urine collection, which
lasted at least 10 minutes, and was replaced with 0.9% saline to
maintain blood volume. At least two to three clearance collec-
tions were taken as indicated during each experimental period
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and averaged, PE 190 or 205 catheters were placed in each
femoral vein for purposes of infusions. Ureters were identified
through a lower abdominal midline incision and cannulated with
PE 190 tubings. Urine was collected separately from each
ureter. The following protocols were used in a total of 24 dogs:
(a.) In nine dogs prepared as described above, a 26 g needle
was also inserted into the left renal artery through a flank
retroperitoneal approach by techniques previously described
for this laboratory [9]. The needle was kept patent with isotonic
saline infused at 0.5 mi/mm when not being used for experimen-
tal infusions. Following three baseline urine collections, ANP
was infused i.v. at 75 ng/kg/min. After a ten minute wait, three
clearance collections were obtained. A 90-minute recovery
period was then allowed and three more urine collections taken.
Hydrochlorthiazide 150 mg prepared in 50 ml of a 50:50
saline:ethanol mixture was then infused intravenously over a 5
to 10 minute period. Preliminary studies had indicated that
maximal diuretic effects could be expected with this dose.
Amiloride 15 mg in 10 ml H20 was infused slowly i.v. over five
minutes as a bolus, followed by a constant infusion of 0.5
mg/mm. Preliminary studies showed that this dose also gave a
maximal effect; larger doses tended to cause severe hypoten-
sion. Bradykinin (BK) 3 p.g/min was infused into the left arterial
cannula at 0.5 mI/mm. Once a stable diuresis ensued (about 30
mm), three urine collections were taken separately from each
catheter. All urine losses were replaced with equivalent vol-
umes of isotonic saline. Following these clearance collections,
ANP was reinfused at the initial dose level and repeat clearance
collections taken as described earlier. Finally, the ANP infusion
was discontinued, and after a 20 minute wait, two final urine
collections were obtained. Thus, in this protocol the right
kidney received intravenous amiloride and thiazide along with
the ANP, while the left kidney received the identical intrave-
nous medications as well as intra-arterial bradykinin. Thus, the
left kidney received all four documented inhibitors of Na
transport within the collecting duct system.
(b.) In six dogs, the order of urine collections was as
described in (a), except that following the initial ANP infusion
and recovery period, bradykinin alone at 3 gImin was infused
into the left renal artery. After a 10 minute wait, urine collec-
tions were taken. The ANP infusion was then restarted, and the
remainder of the protocol was followed as described in (a).
Bradykinin alone was administered since recent studies from
our laboratory [10] had suggested, that at least in sodium
retaining dogs, kinins played a critical role in determining the
natriuretic effects of ANP.
(c.) In four dogs, following the 90-minute recovery period
after the initial ANP infusion, a large dose of mannitol was
infused i.v. at 2.0 ml/min as a 20% solution in water following a
50 ml bolus injection over a five-minute time period. When the
diuresis was well developed, a set of three urine collections was
taken. ANP was then infused, and following a 10-minute
waiting period a set of three urine collections was taken. The
ANP infusion was then discontinued, and after a 20-minute
waiting period, another two clearance periods were collected.
Mannitol was infused throughout the study until termination.
(d.) In five dogs, the study protocol was altered as follows:
through an upper midline abdominal incision each renal artery
was identified after gently mobilizing the intestines, and a 26 g
needle inserted into each renal artery as previously described.
Table 1. Some features of 24 dogs during baseline observation and
ANP infusion
Control ANP
V mllmina 0.8 0.02 2.1 0.04
UNaV p.Eq/min 31 6 223 41
GFR mI/mm 41 3.6 49 4
CpA mI/mm 118 11 138 13
ABP mm Hg 120 4.4 108 3.8a
Plasma protein gIdi 5.2 0.17 5.3 0.19
Hematocrit % 39 3 42 2
Abbreviations are: V, urine flow; UNaV, urinary sodium excretion;
CPAH, PAH clearance, a measure of renal plasma flow.
a P < 0.05 compared to control
Prior to the needle insertions, an arterial Bialock clamp was
placed about the aorta so as to lie above the left renal artery, but
below the right renal artery. The upright clamp was then
sutured to the abdominal wall musculature in order to maintain
position. The intestines were then covered with moist saline
gauzes and the incision closed by clamping opposing muscle
groups with large clamps. The surface of the abdominal wall
was covered with both moist saline gauzes and dry pads over
these. Saline at 0.5 mi/mm was infused through each arterial
needle to maintain patency. Urine was collected separately
from each ureteral catheter. Following the initial ANP infusion
and recovery periods, the clamp was tightened so as to maintain
pressure in the femoral arterial catheter between 80 and 85 mm
Hg. In these experiments only, a separate arterial catheter also
registered ABP in a carotid artery. The bradykinin infusion was
given into each renal arterial needle as previously described and
the other diuretics given i.v. as described in (a). Two clearance
periods were collected from each side following a stable diure-
sis observed for the right kidney. Following this ANP was
administered as previously described and three more urine
collections taken. The ANP was then discontinued, and after a
20 minute wait an additional two urine collections obtained.
Finally, two more clearance periods were collected following
release of the clamp and a 15-minute recovery period.
Inulin, PAH, electrolyte, hematocrit and serum protein were
measured by techniques previously described for this labora-
tory [9]. All data are presented as mean SE. A 5% probability
level was accepted as being significant. Data were analyzed by
analysis of variance for repeated measures and paired or
unpaired t-test as required.
Results
A total of 24 dogs were studied in these experimental proto-
cols. Body weight ranged between 10 to 16 kg with an average
of 13.2 0.36 kg. Table 1 summarizes some features for all dogs
during baseline observations and following the initial exposure
to ANP. Where dogs were studied collecting urine separately
from each kidney, clearance data were summed for both
kidneys. The usual decline in ABP, and increment in hematocrit
is observed following the ANP infusion as is the increase in
sodium excretion. Urine flow on average increased signifi-
cantly. GFR also rose significantly but CPAH did not change. As
indicated in Tables 2 and 3, baseline GFR, CPAH (a measure of
plasma flow and therefore intrarenal microvascular resistance)
as well as urine flow and UNaV were not significantly different,
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Table 2. Clearance data from six dogs receiving bradykinin (BK) into the left renal artery
V mi/mm UNaV jzEq/min GFR mi/mm CPAH mi/mm ABP
L R L R L R L R mmHg
Baseline 0.21 0.04 0.24 0,04 16 1.8 20 1.5 18 1.6 20 1.7 60 2 66 2 118 4.4
ANP 0.76 0.04a 0.80 o.osa 88 3.6a 94 4.l 21 l.3 24 1.3k 64 2.5 68 2.6 105 55
Recovery 0.22 0.02a 0.22 0.ola 20 2.1k 26 2,4a 17 l.8 22 2 64 2.7 64 2.7 115 6
BK 0,84 0.08a 0.21 0.09 90 7.7' 32 3 18 1.7 21 1.6 90 3 65 2.9 115 6.1
BK + ANP 1.7 0.l6a 1.01 0.19a 158 14 114 12 20 1.6 24 l.6 84 3.1 68 2.8 102 79
BK 0.76 0.04a 0.81 0,05a 78 9 40 7.8a 16 1.5k 19 1,4k 80 3.1 61 2.4 110 49a
Abbreviations are: L, left kidney; R, right kidney. Other abbreviations are in Table 1.
a P < 0.05 compared to previous phase
Table 3. Clearance data from nine dogs receiving combined infusions of diuretics and ANP
V mi/mm UNaV jxEq/min GFR mi/mm CPAH mi/mm
L R L R L R L R
ABP
mmHg
Baseline 0.18 0.09 0.20 0.10 35 16 24 14 23 1.6 24 1.3 64 4 70 4.8 130 7
ANP 0.75 010b 0.90 012b 110 12b 96 12'' 27 1.8" 28 1.4" 56 5 72 6.1 110 9b
Recovery 0.28 0.13" 0.29 0.16" 24 5b 26 6" 18 1.9" 19 1.3" 60 3.8 65 5.5
Diureticsa 1.61 0.50" 1.81 0.56" 186 46" 200 37" 18 1.7 17 1.9 60 3.6 63 5.7
130 6.8"
130 6.6
Diuretics + ANP 3.00 0.60" 2.93 0.64" 366 56" 400 50" 17 1.7 18 1,8 50 7.1 55 4.8 120 5.5"
Diuretics 1.63 0.48" 1.7 0.63" 189 47" 209 46" 18 1.4 16 2 51 8 53 5 115 4.9
Abbreviations are in the legends of Tables 1 and 2.
a
During "diuretic" phases, the right kidney received i,v. amiloride and thiazide, while the left kidney received these two diuretics plus
intra-arterial bradykinin.
b P < 0.05 compared to previous phase
thus indicating that placement of the infusion needle into the left
renal artery did not compromise function of that kidney.
Table 2 summarizes data from six dogs where bradykinin was
infused into the left renal artery following the recovery period,
and the repeat ANP infusion is administered concurrent with
this bradykinin infusion. ABP declined significantly during each
ANP infusion, but otherwise remained unchanged. Hematocrit
and serum protein remained constant throughout the study.
CPAH increased only during the bradykinin infusion, but other-
wise remained unchanged. LUNaV for each kidney was identi-
cal following the initial ANP infusion. Bradykinin caused an
ipsilateral diuresis and natriuresis. When ANP was readminis-
tered, there was no significant difference for the right kidney
between the initial and repeat natriuretic responses (for second
response the "BK only" period was used as the baseline). The
left kidney was also able to excrete further sodium in response
to the repeat ANP infusion. The second LUNaVof68 EqImin,
however, was not different from the initial natriuretic response
to ANP (UNaV = 72 Eq/min) P > 0.05. It was slightly
depressed (P < 0.05) compared to the response from the right
kidney.
Table 3 summarizes data from nine dogs where thiazide and
amiloride were given together intravenously but where brady-
kinin was simultaneously administered into the left renal artery.
Thus, varying degrees of inhibition of Na' transport can be
compared between kidneys in the same animal. For each
kidney, there was a significant natriuresis following the admin-
istration of the diuretic agents. When ANP was superimposed,
there was a magnification of the natriuretic response to this
peptide for each kidney. Upon discontinuation of the ANP
reinfusion, the magnitude of the urinary sodium excretion
returned to previous pre-ANP levels. There was no difference
between kidneys in the natriuretic response to the ANP reinfu-
sion.
Table 4 summarizes the data from four dogs receiving a
mannitol load. The data obtained in this study with normal dogs
is similar to that recently collected by us in chronic caval dogs
with ascites responsive to ANP [11]. The mannitol load dramat-
ically increased the level of natriuresis. When ANP was added,
there was a further magnification of the natriuresis indicating
the profound effect of augmented delivery.
To account for the separate effects of delivery, we repeated
studies where i.v. amiloride and thiazide was infused with
additional bradykinin given into each renal artery, but where
blood flow to the left kidney was partially clamped so as to
prevent increased delivery to the CCD and IMCD. Table 5
summarizes these data. When filtered load of Na was below
that of the control kidney, so that the natriuresis must have
been due to reduced tubular reabsorption of Na only, ANP
still was able to further augment UNaV by 46 1 ttEqImin. This
compares to an initial LUNaV following ANP of 80 3.1
Eq/min (P <0.05).
Figure 1 summarizes for purposes of comparison, the amount
of excreted sodium compared to the Na load delivered to the
CCD for some of the experimental phases in this group of dogs
where the clamped left kidney was compared to the right
kidney. For purposes of comparison it is assumed that 5% of the
filtered Na load is being delivered to the CCD. This is clearly
an underestimation where the three diuretic agents are being
used. The implication for this is given in the legend to Table 1.
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Table 4. Clearance data in four dogs receiving mannitol
V UNaV ABP
GFR CPAH Plasma Hematocrit
mi/mm pEqimin mm Hg mi/mm protein gidi %
Control 1.9 0,19 33 3.6 114 4.4 37 113 127 23 5.1 0.17 47 1.7
ANP 2.2 0.23 214 36 106 s.la 44 l.7 134 19 5.1 0.17 50 1.5
Recovery 1.7 0,30a 47 2.9a 115 3,9a 38 l.9a 110 27 5.2 0.l9a 50 1.5
Mannitol 4.1 0.78a 99 8.3a 112 3.7 33 2.l 130 33 4.6 0.l8a 44 1.3a
Mannitol + ANP 7.7 0.91a 440 5l 110 4.4 31 1.4 137 18 4.6 0.17 46 1.2
Mannitol 5.0 0.99a 120 3.6a 102 47 29 1.9 129 17 4.7 0.17 45 1.1
Abbreviations are in Table 1.
a P < 0.05 compared to previous phase
Table 5. Effects of reduced filtered Na load on the natriuretic response to diuretics and ANP in five dogs
Femoral GFR mi/mm FL. Na pEq/mina UNaV ,aEq/min
mmHg L R L R L R
Control 120 4.4 19 1.3 21 1.6 2660 141 2940 162 19 2 23 2.6
ANP 110 51d 23 1.7" 25 1.8" 3174 190" 3450 196d 99 3.5" 106 6"
Recovery 118 4.6" 18 1.4" 19 1.5" 2502 143" 2641 166" 23 3d 27 2.9"
Diuretics: clamped (L) 81.6 0.61" (114 5)C 10 0.9" 18 1.3 1400 88d 2548 157 86 3.5' 204 11"
kidney"
Diuretics + ANP: clamped 82.3 0.55 (106 6.1)" 10 1.0 21 1.4 1434 79 2966 180d 132 6" 372 12,5d
(L) kidney
Diuretics: clamped (L) 81.4 0.49 (104 5.5)" 9 1.0 17 1.3" 1269 122 2370 139" 88 4.8" 212 9.5"
kidney
Diuretics: release clamp 108 4.6" 15 1.2" 16 1.4 2100 127" 2252 137 190 10" 204 11.5
For some abbreviations see legend of Table 1.
a F.L., filtered sodium load
b Diuretics refer to i.v. infusion of amiloride and thiazide and bradykinin delivered into each renal artery.
c ABP data in brackets refer to recording obtained from carotid artery simultaneous with the femoral arterial reading.
d P < 0.05 compared to previous phase
Discussion
A natriuretic response to an infusion of ANP usually does not
appear if several important parameters are displaced from a
well defined narrow physiological range. These include arterial
blood pressure, renal perfusion, GFR, the circulating plasma
volume, the status of the renin-angiotensin system, the status of
circulating catecholamines and the activity of renal efferent
sympathetic nerves [12, 13]. As well, patients or experimental
animals with extensive edema or urinary sodium retention
either do not respond to ANP or show marked attenuation of
the natriuretic response [7, 14]. In these latter groups, recent
evidence suggests that luminal delivery of ANP and/or kinins to
the IMCD and excessive destruction of ANP by proximal
tubular neutral endopeptidase 24:11 may be of critical impor-
tance in determining tubular responses to infused natriuretic
peptide [10, 151.
No matter what the final modulators of ANP activity are, it is
clear that the magnitude of the increment in urinary sodium
excretion following an infusion of this peptide is largely depen-
dent upon two distinct variables: the delivery of Na to the
terminal collecting duct, that is, the IMCD and the degree of
inhibition of Na tubular transport at that site by the peptide.
The former variable is dependent upon the magnitude of the
filtered Na load and the extent of Na reabsorption at sites
proximal to the terminal collecting duct system, while the latter
variable is influenced by physiological factors which may
modulate receptor number, affinity, signal transduction or the
access of Na to transport sites [2].
Available evidence suggests that there is marked disparity
between the existence of ANP receptor sites and an effect on
the transport of Na. Though somewhat controversial [3], most
evidence supports the view that ANP receptor sites, ANP-
stimulated cGMP production and ANP receptor-guanylate cy-
clase mRNA can be identified within glomeruli, the terminal
IMCD, the early IMCD, the CCD, the thin limbs of Henle's
loop (inner medulla), the thick ascending limbs, and S2 proxi-
mal tubule segments [3, 16]. Though these findings suggest the
possibility of ANP induced effects on Na transport at these
various segments, most investigators believe that ANP acts
largely on the IMCD and to a lesser extent, the CCD [1, 2, 17].
Knepper, Lankford and Terada in a recent review come to the
same conclusion [31.
In the absence of an augmented filtered Na load following
ANP, most [1, 17] but not all evidence [18] suggests that there
is no additional delivery of Na to the collecting ducts. Avail-
able evidence suggests that ANP does not inhibit proximal
tubular Na transport unless these segments are exposed to
large amounts of angiotensin or norepinephrine [3, 19, 201.
More recently, Nonoguchi, Tomito and Marumo [21] have
provided evidence that, in rat nephron segments studied in vitro
by incubation and perfusion techniques, ANP may inhibit
antidiuretic hormone-stimulated electrogenic C1 transport in
Fig. L Comparison of excreted sodium load
() to the quantity of Na (U) delivered to
the CCD. It is assumed that this latter
variable is 5% of the filtered Na load, clearly
an underestimate where thiazide, BK and
amiloride are being used. The left kidney had
filtered Na load controlled by aortic
clamping during the administration of diuretics
and the ANP reinfusion; the right kidney was
used as the corresponding control. ANP
decreases Na transport along the CCD and
IMCD. Where excreted load exceeds
"calculated" delivered Na load to the CCD
during the diuretic administration, there
clearly was augmented Na delivery from
more proximal segments. Note during this
latter experimental phase, that the excreted
Na load for the control (right) kidney
exceeds the value for the left kidney, whether
ANP is present or not. This presumably
reflects augmented distal delivery in the
unclarnped kidney, For the diuretic phase as
well, the difference between "delivered" and
excreted Na loads gives an approximate
estimate of diuretic-induced Na delivery
from nephron sites proximal to the CCD. For
each pair of bars, there is statistical
significance (P < 0.05) in each experimental
phase.
thick ascending limbs from only long loops of Henle. Unstim-
ulated Cl transport was not affected. Whether this observation
is relevant to in vivo kidney physiology remains to be clarified.
Given the uncertainty of whether ANP can act at transport
sites separate from the CCD and IMCD, and given the disparity
between physiological findings and histochemical localization
of cGMP production, we thought it of interest to determine
whether ANP could still cause a physiological perturbation,
that is, increase the urinary excretion of sodium in the presence
of extreme (if not total) inhibition of those transport pathways
for Na which can be acted upon by this peptide. In the IMCD,
Na is reabsorbed by an active electrogenic mechanism, with
Na entry into the cells occurring through luminal conductive
channels [5]. This pathway is blocked specifically by amiloride
[5] and by kinins [22]. In the CCD evidence suggests that Na
is transported by both electrogenic and electroneutral path-
ways, inhibitable by ANP, kinins, thiazides and amiloride. If
these transport pathways were largely inhibited by the presence
of bradykinin, thiazide and amiloride, then in the absence of
augmented distal delivery of Nat, ANP should have no (or only
a slight) further effect. This would be true to the extent that:
(a) there truly is no further augmentation of the distal delivery
of Na;
(b) the existing transport pathways susceptible to ANP inhi-
bition are completely inhibited;
(c) no other transport pathways (not inhibited by kinins,
thiazide or amiloride) exist.
In our present studies, the administration of ANP in the
presence of bradykinin alone, or amiloride and thiazides alone
was associated with a further natriuretic response. In the latter
protocol the fractional excretion (FE) of Na during the "re-
covery" phase (Table 3) was 0.9%. This increased to 8.1%
during administration of the diuretics and increased further to
15.9% when ANP was present. A generous assumption for the
fraction of filtered Na load arriving at the CCD under normal
conditions would be approximately 5%. During the combined
"diuretics + ANP" phase, 5% of the filtered load would be 126
Eq/min. Since 400 jtEq/min was being excreted, it is clear that
there was increased delivery of Na to the CCD. When all three
diuretic agents were present (left kidney), the FE of Na was
7.4% (diuretic phase only), which increased to 15.4% when
ANP was added. Again, UNaV was so much more than could be
expected from complete inhibition of the collecting duct (as-
suming 5% of filtered load delivered to early CCD), that there
clearly was augmented Na delivery to that nephron segment.
Whether only amiloride and thiazide were being administered,
or these two diuretics plus bradykinin, the UNaV for each
kidney was not significantly different following the ANP rein-
fusion. Presumably the increment in Na delivery over-
whelmed any extra inhibitory effect in the collecting ducts due
to bradykinin alone, resulting in equivalence of natriuretic
response to the second ANP infusion.
That increased delivery to the CCD and IMCD is important in
determining the natriuretic response to ANP may be observed
from the data obtained in the mannitol experiments (Table 4)
where a modest increment in Na delivery to the collecting
duct system permitted a significant increment of UNaV follow-
ing the ANP reinfusion. This confirms our recent experience
with chronic caval dogs with ascites and showing lack of
response to ANP [11]. The infusion of a "small" load of
mannitol (sufficient to increase UNaV by 10 p.Eq/min then
permitted a UNaV of 42 iEq/min to ANP reinfusion, when
initially this variable was 1 Eq/min. When a "large" mannitol
load was given, sufficient to increase AUNaV by 237 Eq/min,
LUNaV to an ANP reinfusion was 57 pEq/min, where initially it
had been 6 Eq/min. That distal delivery was not the only
modulating factor, and that other factors were important in the
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lack of natriuretic response to ANP in this group of ascitic
animals was determined by giving an identical large mannitol
load to caval dogs initially responding to ANP (LUNaV = 139
pEq/min). While mannitol increased UNaV by 260 pEq/min (a
value similar to the refractory group) the ANP reinfusion
magnified the increment in UNaV to 750 Eq/min compared to
57 Eq/min in caval dogs initially unresponsive to ANP. Morali
et al [23] have also recently shown in cirrhotic patients unre-
sponsive to ANP that a mannitol and ANP infusion will not
induce a natriuresis in all patients.
To assess the importances of augmented distal Na delivery
on the natriuretic effeci of ANP during extreme inhibition of
collecting duct sodium transport, filtered Na load to the left
kidney was held constant by aortic clamping while 3 diuretic
agents were being infused (Table 5). Since filtered Na load did
not significantly change between this latter experimental phase
and the addition of ANP, then any increment in distal Na
delivery to the CCD which occurred between the ANP reinfu-
sion period and the preceeding "recovery" phase will have
already occurred during the initial set of clearance periods while
the diuretics were being infused. This is true to the extent that
ANP does not depress tubular transport of Na proximal to the
CCD, and the diureti' effect remains constant. This latter
assumption seems correct, since as indicated in Table 5, stop-
ping the ANP reinfusion in the face of continuing diuretic
administration returned UN0V to the same values recorded
prior to the second ANP dose. Despite such apparent constancy
in the delivery of Na to the CCD, there was a further
increment in UNaV of 46 Eq/min (P < 0.05) from the previous
diuretic-induced natriuresis. This compares to an increment in
UNaV of 168 .tEq/min from the controlateral unclamped
kidney following the addition of ANP to the diuretic regime.
The increment in UNaV observed from the left kidney following
the ANP reinfusion could have one of two explanations, if one
assumes that ANP has only a distal effect. ANP was either
acting on Na transport pathways not inhibited by the combi-
nation of thiazide, amiloride and bradykinin, or these agents in
combination did not maximally inhibit recognized Na trans-
port occurring along conductive channels or by electroneutral
synporters permitting a potentiating effect from ANP. Our data
do not allow us to choose between these two possibilities.
As indicated in Table 5, the filtered Na load for the clamped
experimental kidney is constant between the "diuretics only"
phase and the next phase where ANP is reinfused. If, during
these two phases, one assumes constancy of distal Na deliv-
ery, however, then it is clear that the increment in UNaV
observed between these two phases must represent an incre-
ment in fractional Na1 excretion, which suggests an ANP effect
distally, that is, in the collecting ducts.
The above conclusion is correct only if ANP does not
interfere with Na transport proximal to the CCD. Given the
uncertainty in this area, previously discussed, one must there-
fore be circumspect with regard to the conclusions derived from
our data. It is nevertheless, of interest to perform some simple
calculations. If one assumes that 5% of the filtered Na load
reaches the early CCD [3], then for the left kidney of the
animals reported in Table 5, this value would be approximately
133 zEq/min, increasing to 159 .tEq/min following the initial
ANP infusion. Since ANP is thought to inhibit between 33 and
66% of net sodium absorption normally occurring across the
collecting ducts [24], the excreted load during this latter exper-
imental phase (99 Eq/min) would represent 62% inhibition of
the distal load delivered to the CCD. During the period of
"clamping and diuretics", the calculated Na load delivered to
the CCD would be approximately 70 EqImin. Since UNaV
during this experimental phase was 86 EqImin, there was in all
certainty, close to 100% inhibition of the Na load delivered to
the CCD plus an increment in the delivered load from more
proximal sites. Similar conclusions can be drawn about the next
phase when ANP was added, except that filtered Na load did
not increase and any increment in the Na load to the CCD had
already occurred when the diuretics had been infused. Again,
we are assuming that ANP does not inhibit tubular Na
tran sport proximal to the CCD. It is of interest to observe that
the modest natriuretic response to the second ANP infusion
occurred in the clamped kidney in the presence of reduced GFR
and reduced perfusion pressure.
In summary, when only some of the known inhibitors of Na
transport in the CCD and IMCD are administered, ANP is
capable of causing a marked increment in UNaV. When all three
(thiazide, amiloride and bradykinin) are present, ANP is still
capable of augmenting U NOV. This is probably due in part to a
concomitant increase in distal Na delivery. When a "deliv-
ery" effect is controlled for by clamping the left renal artery,
the increment in UNaV following ANP is much reduced, but still
present. We conclude that ANP may still increase UNaV when
there is little increase in the distal delivery of Na and in the
presence of extreme inhibition of Na transport within the
collecting duct system. We conclude that either ANP is acting
upon transport pathways not inhibited by the three agents
employed, or that these agents did not produce complete
inhibition of Na transport at their active sites. Our experimen-
tal design does not allow further differentiation, though the
extreme inhibition of Na transport when all three blockers are
present would suggest that there was virtually complete inhibi-
tion of Na transport within the collecting duct. It must be
emphasized that based on the experimental design and the data
obtained, we cannot exclude a more proximal effect of ANP
either on the proximal tubule or the loop of Henle. Though of
interest that ANP may result in an additive natriuretic effect
under conditions of controlled and limited distal Na delivery,
it cannot be concluded that this natriuretic peptide would be of
use in clinical refractory edema where potent diuretics are being
employed.
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